Vasorelaxation

Senkyunolide A
Catalog No: CFN99594

Senkyunolide A is a useful standard compound for the quality evaluation and chemical differentiation between Rhizoma chuanxiong and Angelica sinensis, and suitable for the analysis of a large number of samples. Senkyunolide A has the vasorelaxation activity in contractions to various contractile agents in rat isolated aorta.

Eriodictyol
Catalog No: CFN99719

Eriodictyol has vasodilator, anti-inflammatory and antioxidant activities, it is an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance, it attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats. It may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.

Alismoxide
Catalog No: CFN99775

Alismoxide shows an inhibitory effect on the contraction of isolated bladder smooth muscle induced by carbachol; it demonstrates cytostatic action in HeLa cells, revealing potential use in virostatic cocktails. Alismoxide has inhibitory effects on vascular contraction induced by high concentration of KCl; it also shows an inhibitory effect on the direct passive Arthus reaction (DPAR) in rats in the type III allergic model.

Fraxinellone
Catalog No: CFN99782

Fraxinellone is a selective blocker of voltage-dependent Ca2+ channel, which possesses antimicrobial, anti-inflammatory, neuroprotective and vasorelaxing activities, Fraxinellone exhibits a variety of insecticidal activities including feeding-deterrent activity, inhibition of growth, and larvicidal activity. It inhibited the production of iNOS, COX-2, NF-kappa B, and PGE(2).

Ligustilide
Catalog No: CFN99932

Ligustilide possesses neuroprotective, vasorelaxation, antinociceptive and anti-inflammatory activities, it blocked the activation of MAPKs/IKK and the downstream transcription factors AP-1 and NF-κB. It has the potential to be developed into an effective drug for the treatment of various pain syndromes including primary dysmenorrhoea.